| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | - | 20,353 | ||
| General and administrative | - | 7,030 | ||
| Total operating expenses | - | 27,383 | ||
| Loss from operations | - | -27,383 | ||
| Other income (expense), net | - | 4 | ||
| Interest income | - | 3,350 | ||
| Total other income, net | - | 3,354 | ||
| Loss before income taxes | - | -24,029 | ||
| Income tax expense | - | 64 | ||
| Net loss | -24,635 | -24,093 | ||
| Net unrealized gain on available-for-sale securities, net of tax | 135 | - | ||
| Foreign exchange translation adjustment, net of tax | -4 | - | ||
| Comprehensive loss | -24,504 | - | ||
| Earnings per share, basic, total | -0.27 | -0.26 | ||
| Earnings per share, diluted, total | -0.27 | -0.26 | ||
| Weighted average number of shares outstanding, basic, total | 91,701,529 | 91,575,039 | ||
| Weighted average number of shares outstanding, diluted, total | 91,701,529 | 91,575,039 | ||
Terns Pharmaceuticals, Inc. (TERN)
Terns Pharmaceuticals, Inc. (TERN)